Cancers, Vol. 11, Pages 174: Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review

Cancers, Vol. 11, Pages 174: Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review

Cancers doi: 10.3390/cancers11020174

Authors: Denise Fabian Maria del Pilar Guillermo Prieto Eibl Iyad Alnahhas Nikhil Sebastian Pierre Giglio Vinay Puduvalli Javier Gonzalez Joshua D. Palmer

Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.

http://bit.ly/2DP105g